Cargando…

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone

AIMS: In light of the growing recognition of renal disease in thalassemia, it is important to understand the impact of renal impairment on the pharmacokinetics of iron chelators. This study evaluated the pharmacokinetics and safety of the iron chelator deferiprone (DFP) in subjects with renal impair...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fradette, Caroline, Pichette, Vincent, Sicard, Éric, Stilman, Anne, Jayashankar, Shalini, Tsang, Yu Chung, Spino, Michael, Tricta, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Pharmacokinetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137824/ https://www.ncbi.nlm.nih.gov/pubmed/27276421 http://dx.doi.org/10.1111/bcp.13037

Ejemplares similares

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease
por: Soulières, Denis, et al.
Publicado: (2022)

Pharmacokinetics of orally administered single‐dose ponazuril in cats
por: Burlison, Catherine, et al.
Publicado: (2022)

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapy
por: Xu, Xiaoying, et al.
Publicado: (2016)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation
por: Kloprogge, Frank, et al.
Publicado: (2015)

Pharmacokinetics of multiple doses of co‐crystal of tramadol–celecoxib: findings from a four‐way randomized open‐label phase I clinical trial
por: Videla, Sebastián, et al.
Publicado: (2017)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

Single‐dose pharmacokinetics of co‐crystal of tramadol–celecoxib: Results of a four‐way randomized open‐label phase I clinical trial in healthy subjects
por: Videla, Sebastián, et al.
Publicado: (2017)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
por: Badawy, Sherif M., et al.
Publicado: (2021)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting
por: Gilmore, James, et al.
Publicado: (2018)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
por: Tylleskar, Ida, et al.
Publicado: (2021)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas
por: Zhai, John, et al.
Publicado: (2017)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric‐Onset Hypophosphatasia
por: Pan, Wei‐Jian, et al.
Publicado: (2021)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers
por: Chairat, Kalayanee, et al.
Publicado: (2016)

Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain
por: Jonsson, E. Niclas, et al.
Publicado: (2016)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?
por: Germovsek, Eva, et al.
Publicado: (2016)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Pharmacokinetics and Safety of Brexpiprazole Following Multiple‐Dose Administration to Japanese Patients With Schizophrenia
por: Ishigooka, Jun, et al.
Publicado: (2017)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Intravenous Ferric Pyrophosphate Citrate: Equivalence to Administration via Dialysate
por: Marbury, Thomas, et al.
Publicado: (2022)

ADAM, a hands‐on patient simulator for teaching principles of drug disposition and compartmental pharmacokinetics
por: Zuna, Ines, et al.
Publicado: (2017)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
por: Størset, Elisabet, et al.
Publicado: (2014)

Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians
por: Hasunuma, Tomoko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_34b4lecpe3lpop33oohffn0q9v